GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » 3-Year Sharpe Ratio

Circio Holding ASA (OSL:CRNA) 3-Year Sharpe Ratio : -1.25 (As of Jun. 25, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA 3-Year Sharpe Ratio?

The 3-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past three years. As of today (2025-06-25), Circio Holding ASA's 3-Year Sharpe Ratio is -1.25.


Competitive Comparison of Circio Holding ASA's 3-Year Sharpe Ratio

For the Biotechnology subindustry, Circio Holding ASA's 3-Year Sharpe Ratio, along with its competitors' market caps and 3-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Circio Holding ASA's 3-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Circio Holding ASA's 3-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Circio Holding ASA's 3-Year Sharpe Ratio falls into.


;
;

Circio Holding ASA 3-Year Sharpe Ratio Calculation

The 3-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last three years. A stock / portfolio's 3-Year Sharpe Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past three years.


Circio Holding ASA  (OSL:CRNA) 3-Year Sharpe Ratio Explanation

The 3-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past three years. It is calculated as the annualized result of the average three-year monthly excess returns divided by its standard deviation in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Circio Holding ASA 3-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Circio Holding ASA's 3-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Circio Holding ASA Business Description

Traded in Other Exchanges
Address
Saint Olavs plass, Pb. 6887, Oslo, NOR, 0130
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients. The company's pipeline candidate includes circVec and Mutant KRAS.

Circio Holding ASA Headlines

No Headlines